comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 16:25:03 - browse：544

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： J&J to emphasize cancer drugs, stop much of its vaccine research

WSS

Food as medicine: Medically tailored meals may get standardized

Covid vaccine financial winners and losers, from Pfizer to Novavax

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

J&J to emphasize cancer drugs, stop much of its vaccine research

Diagnostic tests are hitting their mathematical limits

hotspot

comprehensive

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Eliminate the waiting period for sterilization covered by Medicaid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

BIO selects John Crowley as new CEO

Medical leaders decry Supreme Court decision on affirmative action

With clinical trial data readouts, here's how to spot spin

ChatGPT in medicine: STAT answers readers' burning questions

Pediatric cancer treatments threatened by a new FDA policy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. Biobank has 500,000 peoples' genome sequences available

leisure time

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

BIO selects John Crowley as new CEO

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

The EPA's new lead rule: How one expert crunched the numbers

Disappointing trial forces Pfizer to pivot on obesity medicine plans

explore

focus

focus

focus